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Introduction: Hyperhomocisteinemia may 
function as an independent factor of endothelial 
dysfunction progress or intensify already existing 
endothelial lesions [1]. Known factors of 
hyperhomocisteinemia correction are quite scarce 
and would rather include only exogenous 
administration of vitamin В6 and folic acid. In 
clinical investigations use of folic acid or 5- 
methyltetrahydrofolate (5-МТHF, active and 
circulating form of folic acid) was the most 
frequently studied subject of research since such 
agents may have potentially favorable influence on 
metabolism of tetrahydrobioptherine (ВН4).  
At the same time occurrence in the recent years 
of the notions of «endogenous inhibition» of 
endothelial NO-synthase (eNOS) and «eNOS 
uncoupling» resulted in intensification of the studies 
aimed at prevention of these factors as key elements 
in endothelial dysfunction correction. Methylated 
equivalents of L-arginine, namely asymmetric 
dimethylarginine (ADMA) and monomethylarginine 
(L-NMMA) are endogenic inhibitors of endothelial 
nitric oxide synthase (eNOS). [2-6] «eNOS 
uncoupling» is change-over of eNOS enzyme 
activity from nitric oxide production to superoxide 
production.  
Among other things limited nitric oxide 
formation may be conditioned by high arginase 
activity. It becomes apparent that in order to reduce 
risks and frequency of cardiac and vascular diseases 
development it is necessary to suppress high arginase 
activity. To that effect it is possible to use inhibitors 
of arginase 2 [7]. 
The earlier studies demonstrated that L-arginine 
efficiently increased activity of endothelial NO-
synthase and nitric oxide production as well as 
prevented endothelial dysfunction development in 
experiment both in the course of monotherapy and in 
combination with antihypertensive agents with use of 
ADMA-like model of L-NAME-induced endothelial 
dysfunction [2-6]. 
Methods: Simulation of homocysteine-induced 
endothelial dysfunction was made by means of daily 
oral administration of methionine in a dose of 3000 
mg/kg over the period of 7 days [1]. The following 
selective inhibitors of arginase 2 were used: 
compounds with laboratory codes С239-0844, 
L207-0208, L207-0210, L207-0322, L207-0404, 
L207-0525, L327-0346 in a dose of 1 mg/kg and 
tadalafil in a dose of 0.1 mg/kg. During the 8
th
 day of 
the experiments the following parameters were 
evaluated: the level of endothelial dysfunction on the 
basis of a design endothelial dysfunction coefficient 
(EDC), the results of functional tests for 
adrenoreactivity and myocardial reserve exhaustion, 
as well as changes in the values of TotalNO and 
eNOS expression [8, 9]. 
Validity of the absolute parameters variation 
was determined by a differential method of variation 
statistics involving determination of mean shift 
values (М), arithmetical mean (±m) and likely error 
probability (р) with use of the Student’s tables. The 
differences were considered to be significant if 
p<0.05. Statistical calculations were performed with 
aid of Microsoft Excel 7.0 program. 
Results: Inhibitors of arginase 2 produced 
moderate reduction effect on arterial pressure and 
EDC. The highest activity was observed for the 
compounds L207-0525, L327-0346 in a dose of 1 
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1.9±0.4 c.u. correspondingly while the controls showed 
3.5±0.4 c.u. (Table 1). At the same time the compounds 
demonstrated cardioprotective effect by preventing 
adrenoreactivity increase and myocardial reserve 
exhaustion as well as negative growth of the values of 
the final nitric oxide metabolites, i.e. NOx and NOS 
expression (Tables 2, 3). Combined use of preparations 
intensified protective effect in regard to prevention of 
EDC increase and arterial pressure decline, as well as 
in regard to the final nitric oxide metabolites NOx and 
eNOS expression, nevertheless cardioprotective effect 
remained unchanged (Tables 1-3). 
 Discussion of the obtained results: As 
Figure 1 shows arginase activity growth may result 
in use of L-arginine necessary for NO production by 
еNOS and consequently in endothelial dysfunction 
progress. Given that decrease of bioavailability of 
NO in case of endothelial dysfunction is 
pathogenetically involved in the whole set of 
cardiovascular diseases intensification of arginase 
2 activity may serve an important initiating factor of 
development of such diseases.
Figure 1. Schematic diagram of the effect of arginase in regulation of NO bioavailability and of function of vascular smooth 
muscle elements.Hyperactivity of arginase assisted by hydrolysis of L-arginine, ornithine and urea reduces L-arginine 
availability for NO-synthase (NOS), thus suppressing NO production.  Absence of L-arginine will also result in eNOS 
«uncoupling» so that the enzyme will produce superoxide instead of NO. Generation of superoxide uncoupled with eNOS as 
well as of NADPH oxidase and peroxynitrite from superoxide and NO will cause the further arginase activity growth. Such 
changes in the aggregate will reduce NO bioavailability and promote endothelial dysfunction. In smooth muscle vascular cells 
ornithine favors more intensive formation of L-proline and polyamines which stimulate cells proliferation. Ang II-angiotensin 
II; BH4, tetrahydrobiopterin; OxLDL, oxidized low-density lipoprotein; LPS, lipopolysaccharide; NADPHox, nicotineamide-
adenine dinucleotide phosphate oxidase; NO, nitric oxide; ONOO-peroxynitrite; VSMC, vascular smooth muscle cell. 
A number of studies using experimental models 
of hypertension [10], atherosclerosis [11], diabetes 
[12] and ageing [13] demonstratively approved that 
arginase activity growth results in progress of 
endothelial dysfunction. Moreover increase of 
cytoplasmic level of arginase II accompanied by 
hypoxia acts as «eNOS decoupling» factors 
[14].  Finally arginase may also inhibit L-arginine 
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delivery in endothelial cells which causes the further 
reduction of availability of substrate for eNOS [14]. 
As was stated above arginase inhibition may 
potentially have favorable effect in case of a number of 
pathological cardiovascular diseases. A therapeutic 
effect of arginase inhibition was studied in a set of 
experimental models of cardiovascular diseases, the 
studies showed positive results. Clinical research data 
are very limited. Proof-of-principle clinical trials were 
performed with local use of arginase inhibitors by 
means of intracutaneous microdialysis in patients with 
coronary disease and type 2 diabetes mellitus [15], 
cardiac failure [16] and hypertension [17]. These 
observations suggest that arginase activity inhibition is 
of great importance in the process of human 
cardiovascular diseases progression   Therefore more 
large clinical trials involving systematical prescription 
of arginase inhibitors have high potential. 
To our opinion the results of arginase inhibitors 
use in case of pulmonary hypertension including 
simultaneous phosphodiesterase 5 inhibitors 
administration may be of the greatest interest. The 
results of our studies provide strong evidence of such 
combination efficiency for endothelial dysfunction 
correction.   
Several pharmacological inhibitors are available 
for experimental studies. They belong to two classes, 
i.e. boric acid and equivalents of Nω–hydroxy L-
arginine [13, 18]. It is important that the arginase 
inhibitors available presently have weak or no 
selectivity for arginase 2, thus their use is limited. For 
this reason it remains unclear which isoforms should 
be used for obtaining the most favorable effect. Since 
both isoforms of arginase I and II have effect on 
vascular system arginase inhibitors of the 2
nd
 
isoform are necessary in order to give 
comprehensive biological evaluation of these ywo 
isoforms. 
In this connection the compounds with new 
chemical structure studied by us are of undoubted 
interest for further investigations. 
In theory arginase inhibition may involve side 
effects particularly if to speak of the role of 
arginase in urea cycle. Nevertheless arginase 
expression and activity in liver is severalfold more 
intensive than in a vessel wall therefore it is 
unlikely that clinically significant doses may 
inhibit hepatic arginase insomuch that will disturb 
urea cycle [13, 18]. This statement is confirmed 
by absence of poisonous effects in case of 
prolonged administration of arginase inhibitors in 
animal models of hypertension [19] and 
atherosclerosis [20]. Moreover continued arginase 
inhibition does not apparently result in 
compensatory increase of the enzyme activity 
[19].
Conclusion: The results of studies are 
indicative of development of an additive effect of 
combined use of selective arginase 2 inhibitors 
and small doses of phosphodiesterase 5 inhibitor 
in respect of homocysteine-induced endothelial 
dysfunction progression.  
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Table 1 
The effect of selective inhibitors of arginase 2 and tadalafil on dynamics of hemodynamic parameters in animal models of homocysteine-induced endothelial 
dysfunction (M±m, n=10). 
Animal groups SBP DBP EDC 
Intact 129.5±2.2 89.1± 1.1 1.1 ± 0.1
Homocysteine-induced endothelial dysfunction (HIED) (n=10) 119.4±2.3* 84.3±2.2 3.5 ± 0.4* 
HIED + С239-0844 1 mg/kg (n=10) 117.4±2.2 79.9±2.1 2.9±0.3* 
HIED   L207-0208  1 mg/kg (n=10) 123.3±2.4 85.3±1.9 2.3±0.5*  
HIED +  L207-0210  1 mg/kg(n=10) 120.3±3.0 85.9±2.4 2.8±0.3* 
HIED +  L207-0322  1 mg/kg (n=1) 125.3±3.2 83.7±2.3 2.7±0.5* 
HIED +   L207-0404 1 mg/kg (n=10) 125.6±3.3 84.7±2.4 2.5±0.2* 
HIED +   L207-0525 1 mg/kg (n=10) 122.4±3.3 84.8±2.3 1.5±0.3# 
HIED +   L327-0346  1 mg/kg(n=10) 127.6±3.1 87.4±2.3 1.9±0.4# 
HIED +   tadalafil 0.1 mg/kg (n=1) 116.9±3.0 80.3±2.4 1.9±0.4# 
HIED + L327-0525  1 mg/kg + tadalafil 0.1  mg/kg (n=10) 124.4±3.6 84.3±2.4 1.2±0.2# 
Remark: SBP - systolic blood pressure (mm hg), DBP - diastolic blood pressure (mm hg), EDC – endothelial dysfunction coefficient (c.u.), * – significant 
difference with intact animals group (р<0.05); # - significant difference with homocysteine-induced endothelial dysfunction (HIED) group (р<0.05). 
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Table 2 
The effect of selective inhibitors of arginase 2 and tadalafil on dynamics of contractility parameters in the course of  exercise testing in animal models  






Intact 189.4±9.1 87.4±10.9 
Homocysteine-induced endothelial dysfunction (HIED) (n=10) 239.2±8.6* 69.1±3.9* 
HIED + С239-0844 1 mg/kg (n=10) 241.5±7.9* 72.0±4.7* 
HIED   L207-0208  1 mg/kg (n=10) 239.1±8.8* 77.1±4.2* 
HIED +  L207-0210  1 mg/kg(n=10) 227.9±8.4* 78.0±4.7* 
HIED +  L207-0322  1 mg/kg (n=1) 229.4±8.5* 79.4±5.0* 
HIED +   L207-0404 1 mg/kg (n=10) 239.1±8.7* 79.6±5.3* 
HIED +   L207-0525 1 mg/kg (n=10) 201.4±6.5# 99.0±4.9# 
HIED +   L327-0346  1 mg/kg(n=10) 201.0±6.3# 97.5±4.5# 
HIED +   tadalafil 0.1 mg/kg (n=1) 197.7±5.9# 98.1±4.7# 
HIED + L327-0525  1 mg/kg + tadalafil 0.1  mg/kg (n=10) 196.8±5.8# 100.1±5.1# 
Remark: * – significant difference with intact animals group (р<0.05); # - significant difference with homocysteine-induced endothelial dysfunction (HIED) 
group (р<0.05). 
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Table 3 
The effect of selective inhibitors of arginase 2 and tadalafil on dynamics of biochemical markers value (TotalNO, eNOS expression) in animal models  
of homocysteine-induced endothelial dysfunction (М±m, n=10). 
Animal groups NOх еNOS expression 
Intact 121.5±10.4 5.4±0.21 
Homocysteine-induced endothelial dysfunction (HIED) (n=10) 82.1±9.4* 2.05±0.21* 
HIED + С239-0844 1 mg/kg (n=10) 82.4±9.3* 2.11±0.22* 
HIED   L207-0208  1 mg/kg (n=10) 92.0±8.9* 1.99±0.32* 
HIED +  L207-0210  1 mg/kg(n=10) 90.0±9.9* 2.17±0.41* 
HIED +  L207-0322  1 mg/kg (n=1) 92.1±9.7* 2.84±0.45* 
HIED +   L207-0404 1 mg/kg (n=10) 92.6±8.3* 2.01±0.66* 
HIED +   L207-0525 1 mg/kg (n=10) 121.7±9.5# 4.17±0.66# 
HIED +   L327-0346  1 mg/kg(n=10) 122.8±9.4# 4.25±0.67# 
HIED +   tadalafil 0.1 mg/kg (n=1) 129.6±9.3# 4.97±0.73# 
HIED + L327-0525  1 mg/kg + tadalafil 0.1  mg/kg (n=10) 137.1±10.0# 5.92±0.87# 
Remark: NOx – final metabolites of NO (micromole/l); еNOS expression (%);* – significant difference with intact animals group (р<0.05); # – significant 
difference with homocysteine-induced endothelial dysfunction (HIED) group (р<0.05). 
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